Relation between clinical characteristics and TCR-β and γ PCR results
Patient no. . | Age at diagnosis, y . | Sex . | Stage . | TCR-β skin . | TCR-β LN . | TCR-γ skin . | TCR-γ LN . | Follow-up, mo . | Course . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 33 | M | IIa | + | - | + | - | 42 | CR | Alive |
| 2 | 76 | F | IIa | + | - | - | - | 98 | CR | Alive |
| 3 | 59 | M | IIa | + | - | + | - | 67 | SD | Alive |
| 4 | 54 | F | IIa | + | - | + | - | 64 | CR | Alive |
| 5 | 57 | M | IIa | + | - | + | - | 41 | SD | Alive |
| 6 | 74 | M | IIb | + | - | + | - | 95 | CR | Alive |
| 7 | 81 | F | IIb | + | + | + | + | 31 | PD, IV | Alive |
| 8 | 52 | M | IIb | + | + | - | - | 28 | PD, IV | DOD |
| 9 | 72 | M | IIb | + | + | + | + | 20 | CR | D |
| 10 | 51 | F | IIb | + | + | + | + | 94 | PD, IV | DOD |
| 11 | 63 | M | III | + | + | + | + | 69 | PD, IV | DOD |
| 12 | 64 | M | III | + | + | + | + | 39 | PD, IV* | Alive |
| 13 | 77 | F | III | + | - | + | - | 99 | CR | Alive |
| 14 | 87 | F | III | + | + | + | + | 74 | PD, IV | DOD |
| 15 | 62 | M | IV | + | + | + | + | 26 | PD | DOD |
| 16 | 45 | F | IV | + | + | + | + | 96 | SD | Alive |
| 17 | 59 | M | IV | + | + | - | - | 46 | SD | D |
| 18 | 54 | M | IV | + | + | + | + | 42 | PD | DOD |
| 19 | 62 | M | IV | + | + | + | + | 30 | PD | DOD |
| 20 | 59 | F | IV | + | + | + | + | 13 | SD | Alive |
| 21 | 71 | M | IV | + | + | + | + | 108 | PD | D |
| 22 | 62 | F | IV | + | + | + | + | 76 | PD | DOD |
| 23 | 57 | M | IV | + | + | + | + | 41 | PD | DOD |
| 24 | 62 | F | IV | + | + | + | + | 90 | SD | Alive |
| 25 | 60 | F | IV | + | + | + | + | 46 | PD | DOD |
| 26 | 58 | M | IV | + | + | + | + | 21 | PD | DOD |
| 27 | 44 | F | IV | + | + | + | + | 89 | PD, IV* | Alive |
| 28 | 64 | F | IV | + | + | + | + | 41 | PD | DOD |
| 29 | 73 | M | IV | + | + | + | + | 38 | PD | DOD |
| 30 | 51 | F | IV* | + | + | + | + | 53 | PD | DOD |
| 31 | 75 | F | IV* | + | + | + | + | 12 | PD | DOD |
| 32 | 72 | M | IV* | + | + | + | + | 31 | PD | DOD |
| 33 | 43 | M | IV* | + | + | + | + | 38 | SD | Alive |
| 34 | 62 | M | IV* | + | + | + | + | 13 | PD | DOD |
| 35 | 59 | M | IV* | + | + | + | + | 18 | PD | DOD |
| 36 | 73 | M | IV* | + | + | + | + | 29 | PD | DOD |
Patient no. . | Age at diagnosis, y . | Sex . | Stage . | TCR-β skin . | TCR-β LN . | TCR-γ skin . | TCR-γ LN . | Follow-up, mo . | Course . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 33 | M | IIa | + | - | + | - | 42 | CR | Alive |
| 2 | 76 | F | IIa | + | - | - | - | 98 | CR | Alive |
| 3 | 59 | M | IIa | + | - | + | - | 67 | SD | Alive |
| 4 | 54 | F | IIa | + | - | + | - | 64 | CR | Alive |
| 5 | 57 | M | IIa | + | - | + | - | 41 | SD | Alive |
| 6 | 74 | M | IIb | + | - | + | - | 95 | CR | Alive |
| 7 | 81 | F | IIb | + | + | + | + | 31 | PD, IV | Alive |
| 8 | 52 | M | IIb | + | + | - | - | 28 | PD, IV | DOD |
| 9 | 72 | M | IIb | + | + | + | + | 20 | CR | D |
| 10 | 51 | F | IIb | + | + | + | + | 94 | PD, IV | DOD |
| 11 | 63 | M | III | + | + | + | + | 69 | PD, IV | DOD |
| 12 | 64 | M | III | + | + | + | + | 39 | PD, IV* | Alive |
| 13 | 77 | F | III | + | - | + | - | 99 | CR | Alive |
| 14 | 87 | F | III | + | + | + | + | 74 | PD, IV | DOD |
| 15 | 62 | M | IV | + | + | + | + | 26 | PD | DOD |
| 16 | 45 | F | IV | + | + | + | + | 96 | SD | Alive |
| 17 | 59 | M | IV | + | + | - | - | 46 | SD | D |
| 18 | 54 | M | IV | + | + | + | + | 42 | PD | DOD |
| 19 | 62 | M | IV | + | + | + | + | 30 | PD | DOD |
| 20 | 59 | F | IV | + | + | + | + | 13 | SD | Alive |
| 21 | 71 | M | IV | + | + | + | + | 108 | PD | D |
| 22 | 62 | F | IV | + | + | + | + | 76 | PD | DOD |
| 23 | 57 | M | IV | + | + | + | + | 41 | PD | DOD |
| 24 | 62 | F | IV | + | + | + | + | 90 | SD | Alive |
| 25 | 60 | F | IV | + | + | + | + | 46 | PD | DOD |
| 26 | 58 | M | IV | + | + | + | + | 21 | PD | DOD |
| 27 | 44 | F | IV | + | + | + | + | 89 | PD, IV* | Alive |
| 28 | 64 | F | IV | + | + | + | + | 41 | PD | DOD |
| 29 | 73 | M | IV | + | + | + | + | 38 | PD | DOD |
| 30 | 51 | F | IV* | + | + | + | + | 53 | PD | DOD |
| 31 | 75 | F | IV* | + | + | + | + | 12 | PD | DOD |
| 32 | 72 | M | IV* | + | + | + | + | 31 | PD | DOD |
| 33 | 43 | M | IV* | + | + | + | + | 38 | SD | Alive |
| 34 | 62 | M | IV* | + | + | + | + | 13 | PD | DOD |
| 35 | 59 | M | IV* | + | + | + | + | 18 | PD | DOD |
| 36 | 73 | M | IV* | + | + | + | + | 29 | PD | DOD |
+ indicates monoclonal; — not clonal; PD, progressive disease; SD, stable disease; CR, complete remission; D, died unrelated to disease; DOD, died of disease.
Patients with Sézary syndrome.